Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in healthy Korean subjects.

What is known and Objective: Dexmedetomidine is a selective alpha2-adrenoreceptor agonist used for sedation in critically ill patients. The current study aimed to evaluate the pharmacokinetics (PKs), pharmacodynamics and tolerability of intravenous dexmedetomidine in healthy Korean subjects. Methods...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Pharmacy & Therapeutics Vol. 37; no. 6; pp. 698 - 704
Autores principales: Lee, S., Kim, B.-H., Lim, K., Stalker, D., Wisemandle, W., Shin, S.-G., Jang, I.-J., Yu, K.-S.
Formato: equations & formulas research tables/charts randomized controlled trial Journal Article
Publicado: Wiley-Blackwell Dec2012
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104430861&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104430861
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02694727
        EV4
      jtl: Journal of Clinical Pharmacy & Therapeutics
      issn: 02694727
      maglogo: Y
    pubinfo:
      dt: Dec2012
      vid: 37
      iid: 6
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        104430861
        83005567
        10.1111/j.1365-2710.2012.01357.x
        NLM22650799
        104430861
      ppf: 698
      ppct: 6
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in healthy Korean subjects.
      aug:
        au:
          Lee, S.
          Kim, B.-H.
          Lim, K.
          Stalker, D.
          Wisemandle, W.
          Shin, S.-G.
          Jang, I.-J.
          Yu, K.-S.
        affil: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea
      sug:
        subj:
          Imidazoles Pharmacokinetics
          Imidazoles Pharmacodynamics
          Administration, Intravenous
          Sedation Methods
          Human
          South Korea
          Randomized Controlled Trials
          Double-Blind Studies
          Visual Analog Scaling
          Imidazoles Blood
          Descriptive Statistics
          Adolescence
          Adult
          Female
          Male
          Middle Age
          Young Adult
          Data Analysis Software
          Linear Regression
          Dose-Response Relationship, Drug
          Funding Source
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Female
          Male
      ab: What is known and Objective: Dexmedetomidine is a selective alpha2-adrenoreceptor agonist used for sedation in critically ill patients. The current study aimed to evaluate the pharmacokinetics (PKs), pharmacodynamics and tolerability of intravenous dexmedetomidine in healthy Korean subjects. Methods: A randomized, double-blind, placebo-controlled study with three parallel dosage groups was conducted. Twenty-four subjects were randomly assigned to placebo or one of three dexmedetomidine dosing regimens, 3 μg/kg/h for 10 min followed by 0·17 μg/kg/h for 50 min (low dose), 6 μg/kg/h for 10 min followed by 0·34 μg/kg/h for 50 min (middle dose) and 3·7 μg/kg/h for 35 min followed by 0·7 μg/kg/h for 25 min (high dose). Serial blood samples for PK analysis were taken up to 12 h. PK parameters were determined using non-compartmental methods (WinNonlin®), and a population PK model was developed using nonmem®. The sedative effect of dexmedetomidine was assessed by Ramsay sedation score and visual analogue scales/sedation. Adverse events, clinical laboratory tests, electrocardiograms, physical examinations and vital signs were monitored for tolerability assessment. Results: Six subjects were assigned to each of the three active treatment group or placebo group. The AUClast of the low-, middle- and high-dose group were 1096·8 ± 119·9 (mean ± SD) ng*h/L, 2643·0 ± 353·2 ng*h/L and 5600·6 ± 411·0 ng*h/L, respectively. PK of dexmedetomidine was best described using a two-compartment model. The typical value of the population model can be calculated using the following equations: central volume of distribution (L) = 19·9 (age/27)0·954, peripheral volume of distribution (L) = 59·4, clearance (L/h) = 33·7 (albumin level/4·3)1·42 and inter-compartment clearance (L/h) = 67·7. Sedative effects were significantly increased by dexmedetomidine compared to placebo. The blood pressure and heart rate were decreased, but oxygen saturation was maintained stable. What is new and Conclusion: Dexmedetomidine shows linear PK characteristics and dose-dependent sedative effects. A two-compartment population PK model was developed for healthy Korean subjects. The PK parameter estimates are similar in Koreans and Caucasians.
      pubtype: Academic Journal
      doctype:
        equations & formulas
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N